Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
A recent study published in the American Journal of Gastroenterology has demonstrated that people diagnosed with eosinophilic esophagitis (EoE) are at a higher risk for anxiety, mood disorders, as well as ADHD. With this…
A new study has examined the long-term impacts of esophageal dilation in eosinophilic esophagitis (EoE). The aim was to uncover the link between dilation and symptom reports. Additionally, the research…
Colette Romero's son is diagnosed with eosinophilic esophagitis (EoE), a rare disease. She discusses how, among the challenges that come with this condition, education has presented extra difficulties. Education and…
In the past, there have been a few case reports and other studies which theorized a potential link between eosinophilic conditions, such as eosinophilic esophagitis (EoE), and Celiac disease, a…
According to a recent article from WFMZ+, the FDA has recently approved Regeneron's supplemental Biologics License Application (sBLA) for Dupixent, granting it priority review. Dupixent, also known by the generic…
A clinical trial recently conducted at the Pediatric Imam Hossein Hospital demonstrated that synbiotics (a mixture of prebiotics and probiotics) can significantly improve symptoms for pediatric eosinophilic esophagitis (EoE) patients.…
Rare diseases can impact many aspects of life, whether that is physical, psychological, educational, or something else. As caregivers are some of the closest people to those with rare diseases,…
According to an article from Healio, studies have proven that budesonide oral suspension (BOS) is a viable treatment option for eosinophilic esophagitis (EoE). Research demonstrated that BOS outperformed placebo in…
It is always exciting to see the onset of a new clinical trial designed to research therapies to fill unmet needs for patients. According to a news release from biotechnology…
In the United States, Orphan Drug designation is granted to drugs or biologics intended to treat, identify, or diagnose rare or life-threatening conditions. "Rare" conditions are those affecting under 200,000…
A recent study has found that when eosinophilic esophagitis is not treated, it can become progressive. These findings demonstrate how important it is for patients to be regularly monitored and…
Recently, the FDA approved an investigational new drug (IND) application for '1104, a first-in-class peptide for the treatment of eosinophilic esophagitis (EoE). Now, Revolo Biotherapeutics will move forward to investigate…
In a news release from June 23, 2021, Revolo Biotherapeutics ("Revolo") shared that the FDA approved an Investigational New Drug (IND) application for the company's '1104 peptide treatment. Altogether, '1104…
According to a recent news release from biopharmaceutical company Arena Pharmaceuticals, Inc. ("Arena"), the company's investigational therapy, etrasimod, received Orphan Drug designation from the FDA. Currently, Arena is evaluating etrasimod…
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
A study published in Physician's Weekly posed the question: is removing milk from the diets of children with eosinophilic esophagitis a preferable treatment option? A team of researchers, led by…
In early February, pharmaceutical company Ellodi Pharmaceuticals ("Ellodi") shared that its drug candidate, APT-1011, received the FDA's Fast Track designation. APT-1011, or fluticasone propionate oral disintegrating tablet, is designed to…
Takeda has just announced that their application to the the FDA for their eosinophilic esophagitis (EoE) investigative therapy has received Priority Review. This therapy is called budesonide oral suspension or…
According to GlobeNewswire, the results from a Phase 1 study of lirentelimab have been released. Allakos developed this medication as a treatment for eosinophilic and mast-cell related diseases. In this…
According to a story from GlobeNewswire, the medication dupilumab (marketed as Dupixent®) has demonstrated potential efficacy in a phase 3 clinical trial as a treatment for eosinophilic esophagitis, a rare…
APT-1011 is a treatment for eosinophilic esophagitis, a condition that currently faces an unmet medical need. The medication was originally developed by TPG Capital, but they created a new company,…
According to a story from Science Codex, a study conducted by a team of researchers associated with the Nemours Children's Health System is emphasizing the benefits of genetic analysis for…
According to a story from Healio, the results of a randomized trial suggest that patients with eosinophilic esophagitis are likely to experience rapid relapse if they stop treatment. This was…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
